Correlation between polymorphisms at interleukin-6 but not at interleukin-10 promoter and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis in Brazilian individuals

Journal of Medical Virology

Volumn 80, Issue 12, 2008, Pages 2141-2146

  Gadelha, Sandra Rocha ^a,b   Alcântara Jr , Luiz Carlos ^a,b   Costa, Gisele Calazans ^a   Acosta, Angelina Xavier ^a,c   Rios, Domingos ^d   Kashima, Simone ^e   Covas, Dimas Tadeu ^e   Galvão Castro, Bernardo ^a,b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^c FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^d UNIVERSIDADE ESTADUAL DO SUDOESTE DA BAHIA   (Brazil)

^e Hemocentro de Ribeirão Preto ^*  (Brazil)

Author keywords

Brazilian populations; HTLV 1; Interleukin 10; Interleukin 6; Polymorphisms

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BRAZIL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1 ASSOCIATED MYELOPATHY; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; TROPICAL SPASTIC PARAPARESIS; VIRUS PATHOGENESIS;

BRAZIL; GENE FREQUENCY; HTLV-I INFECTIONS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PARAPARESIS, TROPICAL SPASTIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SPINAL CORD DISEASES;

HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 57349141951     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21341     Document Type: Article

References (45)

1. Abramson JH, Gahlinger PM. 2001. Computer program for epidemiologists: PEPI. Version 4.0. Salt Lake City, UT: Sagebrush Press.
2. Belluco C, Olivieri F, Bonafe M, Giovagnetti S, Mammano E, Scalerta R, Ambrosi A, Franceschi C, Nitti D, Lise M. 2003. -174 g>c polymorphism of interleukin-6 gene promoter affects interleukin-6 serum level in patients with colorectal cancer. Clin Cancer Res 9:2173-2176.
3. Cox ED, Hoffmann SC, DiMercurio BS, Wesley RA, Harlan DM, Kirk AD, Blair PJ. 2001. Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation 72:720-726.
4. Dourado I, Alcantara LC, Barreto ML, da Gloria Teixeira M, Galvao-Castro B. 2003. HTLV-1 in the general population of Salvador, Brazil: A city with African ethnic and socio-demographic characteristics. J Acquir Immune Defic Syndr 34:527-531.
5. Ershler WB, Keller ET. 2000. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51:245-270.
6. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P. 1998. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376.
7. Font J, Garcia-Carrasco M, Ramos-Casals M, Aldea AI, Cervera R, Ingelmo M, Vives J, Yague J. 2002. The role of interleukin-10 promoter polymorphisms in the clinical expression of primary Sjogren's syndrome. Rheumatology 41:1025-1030.
8. Furukawa Y, Saito M, Matsumoto W, Usuku K, Tanaka Y, Izumo S, Osame M. 2003. Different cytokine production in tax-expressing cells between patients with human T cell lymphotropic virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis and asymptomatic HTLV-1 carriers. J Infect Dis 187:1116-1125.
9. Gabay C. 2006. Interleukin-6 and chronic inflammation. Arthritis Res Ther 8:S2-S3.
10. Gadelha SR, Alcantara LC, Costa GC, Rios DL, Galvao-Castro B. 2005. Ethnic differences in the distribution of interleukin-6 polymorphisms among three Brazilian ethnic groups. Hum Biol 77:509-514.
11. Galvao-Castro B, Loures L, Rodrigues LG, Sereno A, Ferreira-Junior OC, Franco LG, Muller M, Sampaio DA, Santana A, Passos LM, Proietti F. 1997. Distribution of human T-lymphotropic virus type 1 among blood donors: a nationwide Brazilian study. Transfusion 37:242-243.
12. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de Thé G. 1985. Antibodies to human T lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2:407-410.
13. Hoffmann SC, Stanley EM, Cox ED, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. 2002. Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant 2:560-567.
14. Ishihara K, Hirano T. 2002. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 13:357-368.
15. Jahromi MM, Millward BA, Demaine AG. 2000. A polymorphismin the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus. J Interferon Cytokine Res 20:885-888.
16. Jeffery KJ, Usuku K, Hall SE, Matsumoto W, Taylor GP, Procter J, Bunce M, Ogg GS, Welsh KI, Weber JN, Lloyd AL, Nowak MA, NagaiM, Kodama D, Izumo S, Osame M, Bangham CR. 1999. HLA alleles determine human T-lymphotropic virus-I (HTLV-1) proviral load and the risk of HTLV-1-associated myelopathy. Proc Natl Acad Sci USA 96:3848-3853.
17. Jenny N, Tracy RP, Ogg MS, Luong le A, Kuller LH, Arnold AM, Sharrett AR, Humphries SE. 2002. In the elderly, interleukin-6 plasma levels and the -174G > C polymorphism are associated with the development of cardiovascular disease. Arterioscler Thromb Vasc Biol 22:2066-2071.
18. Kitamura A, Hasegawa G, Obayashi H, Kamiuchi K, Ishii M, Yano M, Tanaka T, Yamaguchi M, Shigeta H, Ogata M, Nakamura N, Yoshikawa T. 2002. Interleukin-6 polymorphism (-634C/G) in the promotor region and the progression of diabetic nephropathy in type 2 diabetes. Diabet Med 19:1000-1005.
19. Kodama D, Saito M, Matsumoto W, Sabouri AH, Izumo S, Arimura K, Usuku K, Bangham CR, Osame M. 2004. Longer dinucleotide repeat polymorphism in matrix metalloproteinase-9 (MMP-9) gene promoter which correlates with higher HTLV-1 Tax mediated transcriptional activity influences the risk of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neuroimmunol 156:188-194.
20. Kubaszek A, Pihlajamaki J, Punnonen K, Karhapaa P, Vauhkonen I, Laakso M, The C. 2003. -174G promoter polymorphism of the IL-6 gene affects energy expenditure and insulin sensitivity. Diabetes 52:558-561.
21. Li XH, Gaynor RB. 2000. Mechanisms of NF-kappaB activation by the HTLV type 1 tax protein. AIDS Res Hum Retroviruses 16:1583-1590.
22. Licastro F, Grimaldi LM, Bonafe M, Martina C, Olivieri F, Cavallone L, Giovanietti S, Masliah E, Franceschi C. 2003. Interleukin-6 gene alleles affect the risk of Alzheimer's disease and levels of the cytokine in blood and brain. Neurobiol Aging 24:921-926.
23. Ma W, Lim W, Gee K, Aucoin S, Nandan D, Kozlowski M, Diaz-Mitoma F, Kumar A. 2001. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 276:13664-13674.
24. Meenagh A, Williams F, Ross OA, Patterson C, Gorodezky C, Hammond M, Leheny WA. 2002. Middleton D frequency of cytokine polymorphisms in populations from Western Europe, Africa, Asia, the Middle East, and South America. Hum Immunol 63:1055.
25. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19:683-6765.
26. Mori N, Gill PS, Mougdil T, Murakami S, Eto S, Prager D. 1996. Interleukin-10 gene expression in adult T-cell leukemia. Blood 88:1035-1045.
27. Murphy EL, Hanchard B, Figueroa JP, Gibbs WN, Lofters WS, Campbell M, Goedert JJ, Blattner WA. 1989. Modelling the risk of adult T-cell leukemia/lymphoma in persons infected with human T-lymphotropic virus type I. Int J Cancer 43:250-253.
28. Nishimura M, Maeda M, Matsuoka M, Mine H, Saji H, Matsui M, Kuroda Y, Kawakami H, Uchiyama T. 2000. Tumor necrosis factor, tumor necrosis factor receptors type 1 and 2, lymphotoxin-alpha, and HLA-DRB1 gene polymorphisms in human T-cell lymphotropic virus type I associated myelopathy. Hum Immunol 61:1262-1269.
29. Nishimura M, Matsuoka M, Maeda M, Mizuta I, Mita S, Uchino M, Matsui M, Kuroda Y, Kawakami H, Kaji R, Adachi A, Uchiyama T. 2002. Association between interleukin-6 gene polymorphism and human T-cell leukemia virus type I associated myelopathy. Hum Immunol 63:696-700.
30. Nobuhara Y, Usuku K, Saito M, Izumo S, Arimura K, Bangham CR, Osame M. 2006. Genetic variability in the extracellular matrix protein as a determinant of risk for developing HTLV-1-associated neurological disease. Immunogenetics 57:944-952.
31. Orland JR, Engstrom J, Fridey J, Sacher RA, Smith JW, Nass C, Garratty G, Newman B, Smith D, Wang B, Loughlin K, Murphy ED. 2003. Prevalence and clinical features of HTLV neurologic disease in the HTLV outcomes study. Neurology 61:1588-1594.
32. Osame MK, Usuku S, Izumo N, Ijichi H, Amitani A, Igata M, Matsumoto M, Tara M. 1986. HTLV-1 associated myelopathy, a new clinical entity. Lancet 1:1031-1032.
33. Plothow A, Benvenutti R, Contieri FL, Bicalho MG. 2003. Frequencies at three polymorphic sites of Interleukin-10 gene promoter in Brazilian renal recipients. Transplant Proc 35:2908-2910.
34. Poiesz BJ, Ruscetti FW, Mier JW, Woods AM, Gallo RC. 1980. T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci USA 77:6815-6819.
35. Rafatpanah H, Pravica V, Farid R, Abbaszadegan MR, Tabatabaei A, Goharjoo A, Etemadi MM, Hutchinson IV. 2004. Association of a novel single nucleotide polymorphism in the human perforin gene with the outcome of HTLV-1 infection in patients from northeast Iran (Mash-had). Hum Immunol 65:839-846.
36. Raymond M, Rousset F. 1995. GENEPOP (version 1.2): Population genetics software for exact tests and ecumenicism. J Hered 86:248-249.
37. Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O'Keefe GE. 2003. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 20:218-223.
38. Rosenwasser LJ, Borish L. 1997. Genetics of atopy and asthma: The rationale behind promoter-based candidate gene studies (IL-4 and IL-10). Am J Respir Crit Care Med 156:S152-S155.
39. Sabouri AH, Saito M, Lloyd AL, Vine AM, Witkover AW, Furukawa Y, Izumo S, Arimura K, Marshall SE, Usuku K, Bangham CR, Osame M. 2004. Polymorphism in the interleukin-10 promoter affects both provirus load and the risk of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 190:1279-1285.
40. Saito M, Eiraku N, Usuku K, Nobuhara Y, Matsumoto W, Kodama D, Sabouri AH, Izumo S, Arimura K, Osame M. 2005. ApaI polymorphism of vitamin D receptor gene is associated with susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis in HTLV-1 infected individuals. J Neurol Sci 232:29-35.
41. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ, O'Brien TR, Vlahov D, Buchbinder S, Giorgi J, Rinaldo C, Donfield S, Willoughby A, O'Brien SJ, Smith MW. 2000. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 97:14467-14472.
42. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. 2006. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: The role of T regulatory cells. Immunology 117:433-442.
43. Terry CF, Loukaci V, Green FR. 2000. Cooperative influence of genetic polymorphisms on interleukin-6 transcriptional regulation. J Biol Chem 275:18138-18144.
44. Warle MC, Farhan A, Metselaar HJ, Hop WC, Perrey C, Zondervan PE, Kap M, Kwekkeboom J, Ijzermans JN, Tilanus HW, Pravica V, Hutchinson IV, Bouma GJ. 2003. Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transpl 9:170-181.
45. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. 1997. Genetic influence on cytokine production in meningococcal disease. Lancet 349:1912-1913.